Conditioning Regimens Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity
暂无分享,去创建一个
[1] B. Sandmaier,et al. Costs of Second Allogeneic Hematopoietic Cell Transplantation , 2013, Transplantation.
[2] M. Perales,et al. Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? , 2013, Blood.
[3] T. Arneson,et al. Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation in the United States: A Study Using a Large National Private Claims Database , 2012, Bone Marrow Transplantation.
[4] P. Armand,et al. The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. , 2012, Biology of Blood and Marrow Transplantation.
[5] M. Remberger,et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation , 2012, Bone Marrow Transplantation.
[6] S. Mineishi. Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. , 2011, JAMA.
[7] P. Hari,et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.
[8] J. Wingard,et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.
[9] J. Sierra,et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Sepkowitz,et al. Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated , 2009, Bone Marrow Transplantation.
[11] D. Zahrieh,et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] D. Zahrieh,et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy , 2007, Bone Marrow Transplantation.
[13] M. Remberger,et al. Costs of Allogeneic Hematopoietic Stem Cell Transplantation , 2006 .
[14] I. Durand-zaleski,et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia , 2005, Bone Marrow Transplantation.
[15] S. Chevret,et al. PREDICTING THE COSTS OF ALLOGENEIC SIBLING STEM-CELL TRANSPLANTATION: RESULTS FROM A PROSPECTIVE, MULTICENTER, FRENCH STUDY , 2004, Transplantation.
[16] H. Sengeløv,et al. Haematopoietic stem cell transplantation with non‐myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution , 2004, British journal of haematology.
[17] M. Maris,et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.
[18] T. Gooley,et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. , 2003, Blood.
[19] M. Remberger,et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.
[20] E. Bass,et al. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] H. Welch,et al. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. , 1989, The New England journal of medicine.
[22] S. Goodman,et al. Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.